7-Nitroindazole
Based on 1 publication(s) in Google Scholar
7-Nitroindazole is a selective and BBB-penetrable inhibitor of nitric oxide synthase (NOS) (IC50 = 0.47 μM in mouse cerebellum). 7-Nitroindazole does not affect blood pressure or endothelium-dependent relaxation while inhibiting nNOS in experimental animals. 7-Nitroindazole has anti-injurious and neuroprotective properties, and can be studied in research for neurological diseases such as Parkinson’s disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.09%
- No. CAS: 2942-42-9
- Fòrmula: C7H5N3O2
- Peso molecular:163.14
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-18731
1400W Dihydrochloride
-
HY-18729A
L-NAME hydrochloride
-
HY-101175
3-Bromo-7-nitroindazole
-
HY-100965
Diphenyleneiodonium chloride
-
HY-B1041
Aminoguanidine hydrochloride
-
HY-18734A
Carboxy-PTIO potassium
-
HY-101316
TRIM
-
HY-B1135
Benzbromarone
-
HY-102062
Nω-Propyl-L-arginine
-
HY-12116
L-NIL
-
HY-118700
2-Iminobiotin
-
HY-100986
L-NIO dihydrochloride
Publications Citing Use of MedChemExpress (MCE) 7-Nitroindazole
More
Actividad biológica
|
nNOS |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Astrocyte | EC50 |
282.6 μM
Compound: 34
|
Antiproliferative activity against mouse astrocyte cells by MTT assay
Antiproliferative activity against mouse astrocyte cells by MTT assay
|
[PMID: 17417631] |
| DLD-1 | IC50 |
24 μM
Compound: 7-NI
|
Tested to inhibit the conversion of [3H]L-arginine to [3H]L-citrulline catalyzed by inducible NOS from human DLD-1 cells.
Tested to inhibit the conversion of [3H]L-arginine to [3H]L-citrulline catalyzed by inducible NOS from human DLD-1 cells.
|
10.1016/0960-894X(95)00273-V |
| J774 | IC50 |
20 μM
Compound: 7-NI
|
Tested to inhibit the conversion of [3H]L-arginine to [3H]L-citrulline catalyzed by inducible NOS from mouse macrophage J774 cells
Tested to inhibit the conversion of [3H]L-arginine to [3H]L-citrulline catalyzed by inducible NOS from mouse macrophage J774 cells
|
10.1016/0960-894X(95)00273-V |
| RAW264.7 | IC50 |
>200 μM
Compound: 1
|
Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs
Inhibition of LPS and gamma-IFN-stimulated nitrite accumulation in mouse RAW 264.7 cells after 20 hrs
|
[PMID: 18502134] |
7-Nitroindazole (0.01-100 μM) has obvious inhibitory effect on cerebellar NOS (IC50: 0.47 μM), and is more effective than L-NAME (HY-18729A) (IC50: 0.87 μM) and L-NMMA (HY-18732) (IC50: 2.37 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
7-Nitroindazole (25 mg/kg; Subcutaneous injection; 25 days) improves L-DOPA (HY-N0304)-induced dyskinesias in non-human primate models of Parkinson's disease[2].
7-Nitroindazole (5-20 mg/kg; Intraperitoneal injection; 6 weeks) improves the learning and memory of hypothyroidism rats[3].
7-Nitroindazole (30 mg/kg; Intraperitoneal injection; Single dose) enhances Fos immune response induced by muscle proprioceptive signaling within distinctive regions of the spinal cord in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Formalin treated male LACA mice (28-32 g)[1]
-
Dosage:10, 25, 50 and 80 mg/kg
-
Administration:Intraperitoneal injection (i.p.); single dose
-
Result:Decreased mouse cerebellar NOS activity measured 15 min thereafter by over 55% at a dose of 25 mg/kg.
Inhibition of late phase Formalin-induced hindpaw licking without influencing the early phase response with an ED50 of 26.0 mg/kg.
Did not increase MAP over the 45 min experimental period.
-
Animal Model:MPTP (HY-15608) and Madopar treated adult male cynomolgus monkeys (3.8-4.5 kg)[2]
-
Dosage:25 mg/kg
-
Administration:Subcutaneous injection (s.c.); 25 days
-
Result:Dramatically decreased the intensity and duration of the L-DOPA (HY-N0304) induced dyskinesias (LIDs), reducing the profile by more than 50%.
Did not affect the improvement of Parkinson's disease and significantly reduced LIDs.
-
Animal Model:Propylthiouracil (HY-B0346) treated male Wistar juvenile rats (20 days old)[3]
-
Dosage:5, 10, and 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.); 6 weeks
-
Result:Shortened the escape latency and traveled distance and spent less time and traveled less distance to reach the platform in morris water maze test.
Enhanced the spatial memory of the rats in morris water maze test.
Reduced the time spent in the dark box post shock and diminished the number of entries into the dark box at all times in passive avoidance learning test.
Improved thiol, SOD, CAT, thiol, and BDNF but attenuated MDA and NO metabolites in the brain.
-
Animal Model:Wistar rats (240-290 g)[4]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection (i.p.); single dose
-
Result:Increased the total number of Fos-ir interneurons and motor neurons (per slice), and the greatest increases in the number of Fos-ir neurons were found in the L4 (+100%) and L5 (+105%) segments.
Chemical Information
-
No. CAS 2942-42-9
-
Appearance Solid
-
Peso molecular 163.14
-
Fòrmula C7H5N3O2
-
Color Light yellow to yellow
-
SMILES
O=[N+](C1=CC=CC2=C1NN=C2)[O-]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biomed Pharmacother
R-(+)-WIN55212-2 protects pericytes from ischemic damage and restores retinal microcirculatory patency after ischemia/reperfusion injury. [Abstract]2023 Oct:166:115197. PMID: 37572634
Solvente y solubilidad
DMSO : 100 mg/mL (612.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (287 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Moore PK, et al. 7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol. 1993 Feb;108(2):296-7. [Content Brief]
[2]. Herrero MT, et al. 7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate. Open Biol. 2023 May;13(5):220370. [Content Brief]
[3]. Memarpour S, et al. Neuronal Nitric Oxide Inhibitor 7-Nitroindazole Improved Brain-Derived Neurotrophic Factor and Attenuated Brain Tissues Oxidative Damage and Learning and Memory Impairments of Hypothyroid Juvenile Rats. Neurochem Res. 2020 Nov;45(11):2775-2785. [Content Brief]
[4]. ilyavskii AI,et al. 7-Nitroindazole potentiates c-fos expression induced by muscle tendon vibration in the spinal cord. Muscle Nerve. 2012 Apr;45(4):597-602. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.1297 mL | 30.6485 mL | 61.2970 mL | 153.2426 mL |
| 5 mM | 1.2259 mL | 6.1297 mL | 12.2594 mL | 30.6485 mL | |
| 10 mM | 0.6130 mL | 3.0649 mL | 6.1297 mL | 15.3243 mL | |
| 15 mM | 0.4086 mL | 2.0432 mL | 4.0865 mL | 10.2162 mL | |
| 20 mM | 0.3065 mL | 1.5324 mL | 3.0649 mL | 7.6621 mL | |
| 25 mM | 0.2452 mL | 1.2259 mL | 2.4519 mL | 6.1297 mL | |
| 30 mM | 0.2043 mL | 1.0216 mL | 2.0432 mL | 5.1081 mL | |
| 40 mM | 0.1532 mL | 0.7662 mL | 1.5324 mL | 3.8311 mL | |
| 50 mM | 0.1226 mL | 0.6130 mL | 1.2259 mL | 3.0649 mL | |
| 60 mM | 0.1022 mL | 0.5108 mL | 1.0216 mL | 2.5540 mL | |
| 80 mM | 0.0766 mL | 0.3831 mL | 0.7662 mL | 1.9155 mL | |
| 100 mM | 0.0613 mL | 0.3065 mL | 0.6130 mL | 1.5324 mL |
7-Nitroindazole Related Classifications
HY-69019 Related Classifications
Powered by Bioz